Blog

  • The Copper Peptide Family: GHK-Cu and Its Relatives — A Research Overview

    The copper peptide family, at a glance

    Copper peptides are a small but distinctive group of research peptides defined by one shared feature: they bind a copper ion. The best known is GHK-Cu — the tripeptide glycyl-L-histidyl-L-lysine complexed with copper(II). This overview explains what copper peptides are as research materials, why the copper matters, how the family is grouped, and what a research buyer should check when sourcing them.

    Everything here concerns these peptides as research materials only. The peptides Solis supplies are for laboratory research use only — not for human or veterinary use, and not a medicine, supplement, or cosmetic. Nothing below is medical, dosing, or usage guidance. For the fundamentals of how peptides are defined, see our primer on what peptides are.

    What makes a peptide a “copper peptide”

    The defining feature is a copper-binding motif. In GHK, the histidine residue and the peptide backbone form a site that coordinates a copper(II) ion, producing the blue-tinted GHK-Cu complex. This peptide-copper coordination is the whole reason the family is studied as a distinct group rather than as ordinary short peptides.

    Two labelling points a research buyer runs into:

    • GHK vs GHK-Cu. “GHK” is the bare tripeptide; “GHK-Cu” is the copper complex. They are chemically different materials, and a Certificate of Analysis should make clear which one a vial contains.
    • Copper content. Because the copper is part of the complex, the analytics for GHK-Cu differ from a plain peptide — the ratio and identity of the copper complex matter, not just peptide purity.

    Members of the family

    Across research-peptide suppliers, the copper-peptide category is small and centres on:

    • GHK-Cu. The flagship copper tripeptide, by far the most studied and most widely listed.
    • Related copper-binding sequences. A handful of longer copper-binding peptides appear in the literature, but GHK-Cu dominates the commercial category.

    Because the family is so GHK-centred, most sourcing questions in practice are really questions about GHK-Cu specifically — which our dedicated GHK-Cu profile covers in depth.

    Mechanisms explored in the literature

    Copper peptides are studied chiefly in the context of copper delivery and matrix biology in research models:

    • Copper as a cofactor. Copper is a cofactor for a number of enzymes, and GHK-Cu is studied as a way of presenting copper in a peptide-bound form in experimental systems.
    • Extracellular-matrix research. GHK and GHK-Cu appear in research literature on tissue and matrix remodelling models.

    As always, these are mechanisms examined in research, not approved clinical outcomes. Copper peptides are not approved therapeutics.

    Quality considerations when sourcing copper peptides

    For a research buyer, copper peptides carry one extra layer beyond the usual checks, because the metal complex is part of the product:

    • Identity (mass spectrometry) confirming the peptide sequence for the lot.
    • HPLC purity of ≥98% for the peptide component, shown as a real chromatogram.
    • Copper-complex clarity — whether the material is the copper complex (GHK-Cu) or the free peptide (GHK), documented on the Certificate of Analysis.

    We document our analytics on the Quality & Analytics page, and current copper-peptide formats are in the catalogue.

    Frequently asked questions

    What are copper peptides?

    Copper peptides are short peptides that bind a copper ion, the best-known being GHK-Cu (the tripeptide GHK complexed with copper). In research they are studied as copper-carrying peptide complexes.

    What is the difference between GHK and GHK-Cu?

    GHK is the bare tripeptide; GHK-Cu is the same peptide coordinated to a copper(II) ion. They are distinct materials, and a CoA should specify which one is in the vial.

    Are copper peptides approved drugs?

    No. Copper peptides are handled as research materials for laboratory use only, not as approved medicines.

    What should I check when sourcing a copper peptide?

    Mass-spec identity, ≥98% HPLC purity for the peptide, and clear documentation of whether the material is the copper complex or the free peptide — all on a lot-specific CoA.

    In summary

    Copper peptides are a compact research category defined by copper binding, with GHK-Cu as the flagship. The extra sourcing consideration versus an ordinary peptide is the copper complex itself, which the documentation should spell out. As with any research peptide, what separates products is evidence: ≥98% HPLC purity, mass-spec identity, and a lot-specific CoA. See the Quality & Analytics page or browse the catalogue.

    Solis Peptides supplies research peptides for laboratory research use only — not for human or veterinary use, and not a medicine, supplement, or cosmetic. Nothing in this article is medical, dosing, or usage advice.

  • CJC-1295 vs Sermorelin vs Ipamorelin (Research Comparison)

    Three of the most-searched growth-hormone research peptides — CJC-1295, Sermorelin and Ipamorelin — are constantly compared, and just as constantly confused. The confusion comes from lumping them into one bucket when in fact they split cleanly into two mechanistic families. This comparison lays out where each one sits and why it matters.

    This concerns all three strictly as research materials. The peptides Solis supplies are for laboratory research use only — not for human or veterinary use — and nothing here is medical, dosing, or usage guidance.

    The two families, three peptides

    As covered in our primer on growth-hormone secretagogues, these peptides fall into two families defined by receptor:

    So two of the three act on one receptor, and the third acts on another.

    Sermorelin vs CJC-1295

    Both are GHRH analogues, so they engage the same receptor — the difference is stability and duration. Sermorelin corresponds to the short native GHRH(1–29) fragment and is the shortest-acting. CJC-1295 builds on that backbone with modifications; the DAC version in particular is engineered for a much longer duration of action. In short: same family, different half-life design.

    Where Ipamorelin fits

    Ipamorelin is the odd one out mechanistically — it is a ghrelin mimetic, acting on the GHS-R1a receptor rather than the GHRH receptor, and is noted in the literature for its selectivity. Because it reaches the growth-hormone axis by a different route, it is frequently studied in combination with a GHRH analogue such as CJC-1295, rather than as an alternative to it.

    What to check when sourcing

    For all three, the documentation is identical: ≥98% HPLC purity with the chromatogram, mass-spectrometry identity, and a lot-specific Certificate of Analysis. See our Quality & Analytics page.

    Frequently asked questions

    What’s the difference between CJC-1295 and Sermorelin?

    Both are GHRH analogues acting on the same receptor; they differ mainly in stability and duration. Sermorelin is the short native fragment; CJC-1295 is engineered for longer action, especially in the DAC version.

    How is Ipamorelin different from the other two?

    Ipamorelin is a ghrelin mimetic acting on a different receptor (GHS-R1a), whereas CJC-1295 and Sermorelin are GHRH analogues. That’s why Ipamorelin is often studied alongside a GHRH analogue rather than instead of one.

    Are any of them approved drugs?

    No. All three are handled as research materials for laboratory use only and are not intended for human or veterinary use.

    In summary

    CJC-1295 and Sermorelin are GHRH analogues that differ in duration; Ipamorelin is a ghrelin mimetic on a different receptor, commonly paired with a GHRH analogue. Read the CJC-1295, Sermorelin and Ipamorelin profiles, and remember documentation — ≥98% HPLC, mass-spec identity, a lot-specific CoA — is what separates products. Browse the catalogue.

    Solis Peptides supplies research peptides for laboratory research use only — not for human or veterinary use, and not a medicine, supplement, or cosmetic. Nothing in this article is medical, dosing, or usage advice.

  • BPC-157 vs TB-500: How the Two Repair Peptides Differ

    BPC-157 and TB-500 are the two most-discussed peptides in the tissue-repair research category, and they are almost always mentioned together. That pairing leads many buyers to assume they are interchangeable — but mechanistically they are quite distinct. This article explains why the two are studied side by side, how their research mechanisms differ, and what to check when sourcing either.

    This concerns both peptides strictly as research materials. The peptides Solis supplies are for laboratory research use only — not for human or veterinary use — and nothing here is medical, dosing, or usage guidance.

    Why they’re paired

    BPC-157 and TB-500 are paired because they are the two flagship tool compounds in tissue-repair and angiogenesis research — the overlapping research contexts in which they appear make them natural companions in catalogues and literature reviews. But sharing a research area is not the same as sharing a mechanism.

    How the mechanisms differ

    The key concept is that the two peptides act through different pathways:

    • BPC-157 — a synthetic pentadecapeptide whose research literature centres on the VEGFR2 and nitric-oxide pathways, i.e. vascular and angiogenic signalling.
    • TB-500 — associated with the actin-binding region of thymosin β4, whose research literature centres on actin regulation and cell migration.

    So one is studied primarily around vascular signalling, the other around the cytoskeleton and cell movement. They are different tools that happen to be studied in overlapping repair contexts.

    Which one, and the naming trap

    Because they are studied together, some suppliers offer them as a “blend.” As always, the meaningful information is the documentation, not the marketing. TB-500 carries an extra naming trap: “TB-500” and “thymosin β4” are used loosely, so mass-spec identity data is what tells you which molecule is actually in the vial.

    What to check when sourcing either

    The documentation set is identical for both: ≥98% HPLC purity with the chromatogram, mass-spectrometry identity, and a lot-specific Certificate of Analysis with net peptide content. See our Quality & Analytics page.

    Frequently asked questions

    Are BPC-157 and TB-500 the same?

    No. They are both studied in tissue-repair research, but they act through different pathways — BPC-157 around VEGFR2/nitric-oxide signalling, TB-500 around actin regulation and cell migration.

    Why are they sold together?

    Because they are the two flagship tissue-repair research peptides and appear in overlapping literature, so catalogues commonly list them as a pair.

    Are either of them approved drugs?

    No. Neither is an approved medicine with the major regulators; both are handled as research materials for laboratory use only.

    In summary

    BPC-157 and TB-500 are the two flagship tissue-repair research peptides, paired by research context but distinct in mechanism — vascular/angiogenic signalling versus actin regulation. Read the full BPC-157 and TB-500 profiles, and note that documentation — ≥98% HPLC, mass-spec identity, a lot-specific CoA — is what separates products. Browse the catalogue.

    Solis Peptides supplies research peptides for laboratory research use only — not for human or veterinary use, and not a medicine, supplement, or cosmetic. Nothing in this article is medical, dosing, or usage advice.

  • Growth-Hormone Secretagogues Explained (for Research)

    “Growth-hormone secretagogue” is one of the most common phrases in the research-peptide world, and one of the most useful to actually understand. It is the umbrella term for a whole family of peptides — CJC-1295, Sermorelin, Tesamorelin, Ipamorelin and others — that are studied for their interaction with the growth-hormone axis. This primer explains what the term means, the two mechanistic families inside it, and why they are so often studied together.

    This concerns these peptides strictly as research materials. The peptides Solis supplies are for laboratory research use only — not for human or veterinary use — and nothing here is medical, dosing, or usage guidance.

    What “secretagogue” means

    A secretagogue is simply something that stimulates secretion. A growth-hormone secretagogue is a compound studied for its ability to prompt the release of growth hormone from the pituitary in research models. Crucially, these peptides are studied for engaging the body’s own signalling systems — not for being growth hormone themselves.

    The two families

    Almost every research growth-hormone secretagogue falls into one of two mechanistic families, defined by which receptor it engages:

    • GHRH analogues. These mimic growth-hormone-releasing hormone and act on the GHRH receptor. The group includes Sermorelin, CJC-1295, and Tesamorelin — they differ mainly in how they are stabilised.
    • Ghrelin mimetics (GHRPs). These mimic ghrelin and act on the GHS-R1a (ghrelin) receptor. The best-known example is Ipamorelin, noted in the literature for its selectivity.

    Understanding this split is the single most useful concept in the category: it explains why some peptides are grouped together and others are treated as complementary.

    Why they’re studied in pairs

    Because the two families reach the same axis through different receptors, they are frequently studied as a pair — for example a GHRH analogue alongside a ghrelin mimetic. The logic in the research literature is that engaging two separate routes into the growth-hormone axis is mechanistically distinct from engaging one twice. This is why catalogues so often list CJC-1295 and Ipamorelin together.

    What to check when sourcing

    Whichever family a secretagogue belongs to, the documentation that matters is the same: ≥98% HPLC purity (with the chromatogram), mass-spectrometry identity, and a lot-specific Certificate of Analysis. We document all of this on our Quality & Analytics page.

    Frequently asked questions

    What is a growth-hormone secretagogue?

    A compound studied for stimulating the release of growth hormone from the pituitary in research models, by engaging the body’s own signalling receptors rather than being growth hormone itself.

    What are the two families?

    GHRH analogues (acting on the GHRH receptor — e.g. Sermorelin, CJC-1295, Tesamorelin) and ghrelin mimetics or GHRPs (acting on the ghrelin receptor — e.g. Ipamorelin).

    Why are GHRH analogues and GHRPs studied together?

    Because they reach the growth-hormone axis through two different receptors, so they are mechanistically complementary rather than redundant.

    In summary

    Growth-hormone secretagogues are a family of research peptides split into two mechanistic groups — GHRH analogues and ghrelin mimetics — that engage the growth-hormone axis through different receptors, which is why they are so often studied in pairs. See the individual profiles for CJC-1295, Sermorelin, Tesamorelin and Ipamorelin, or browse the catalogue.

    Solis Peptides supplies research peptides for laboratory research use only — not for human or veterinary use, and not a medicine, supplement, or cosmetic. Nothing in this article is medical, dosing, or usage advice.

  • KPV: A Research Profile (Alpha-MSH Tripeptide Fragment)

    KPV is a very short peptide with an outsized presence in inflammation-research literature. It is the C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (α-MSH), and it is studied as a tool compound for probing inflammatory-signalling pathways. This profile explains what KPV is, what is studied, and what to check when sourcing it.

    This concerns KPV strictly as a research material. The peptides Solis supplies are for laboratory research use only — not for human or veterinary use — and nothing here is medical, dosing, or usage guidance.

    What is KPV?

    KPV is a tripeptide — just three amino acids, Lysine-Proline-Valine — corresponding to the C-terminal fragment of α-MSH. Despite its small size, it retains research interest because that fragment is associated with the anti-inflammatory activity studied in the α-MSH literature. For the fundamentals of peptide fragments, see our primer on what peptides are.

    Mechanisms explored in the literature

    The KPV research literature centres on inflammation:

    • Inflammatory-signalling pathways. KPV is studied for its reported influence on inflammatory-signalling cascades (such as NF-κB-related pathways) in preclinical models.
    • Melanocortin-fragment activity. As an α-MSH fragment, KPV appears in research on the melanocortin system’s role in inflammation.

    These are mechanisms studied in preclinical research, not approved clinical outcomes. KPV is not an approved therapeutic.

    What’s on the market

    KPV is typically sold as lyophilised powder in sealed vials. Research-grade material should be ≥98% HPLC with a batch Certificate of Analysis. Because it is a short, inexpensive peptide, documentation quality varies widely across suppliers.

    Quality considerations when sourcing KPV

    The standard documentation set applies: mass spectrometry for identity, HPLC purity of ≥98% shown as a chromatogram, and a lot-specific Certificate of Analysis with net peptide content. See our Quality & Analytics page, and current formats in the catalogue.

    Frequently asked questions

    What is KPV?

    KPV is a tripeptide (Lys-Pro-Val) corresponding to the C-terminal fragment of alpha-MSH. In research it is studied as a tool compound for inflammatory-signalling pathways.

    Is KPV an approved drug?

    No. KPV is not an approved medicine with the major regulators. It is handled as a research material for laboratory use only.

    What is KPV studied for?

    In preclinical research it is examined for its reported influence on inflammatory-signalling pathways associated with the melanocortin system. These are research findings, not approved clinical uses.

    In summary

    KPV is a short α-MSH-derived tripeptide studied in preclinical research for inflammatory-signalling pathways. It is not an approved therapeutic, and documentation — ≥98% HPLC purity, mass-spec identity, a lot-specific CoA — is what separates products. See our Quality & Analytics page or browse the catalogue.

    Solis Peptides supplies research peptides for laboratory research use only — not for human or veterinary use, and not a medicine, supplement, or cosmetic. Nothing in this article is medical, dosing, or usage advice.

  • Selank: A Research Profile (Tuftsin Analogue)

    Selank is the companion peptide to Semax in the nootropic-research category — another synthetic regulatory peptide developed in Russia, but derived from a different natural molecule. Its research literature centres on anxiety-related and immunomodulatory pathways. This profile explains what Selank is, what is studied, and what to check when sourcing it.

    This concerns Selank strictly as a research material. The peptides Solis supplies are for laboratory research use only — not for human or veterinary use — and nothing here is medical, dosing, or usage guidance.

    What is Selank?

    Selank is a synthetic heptapeptide based on tuftsin, a naturally occurring immune-active peptide fragment, with a stabilising tail added for research durability. Like Semax, it follows the “stabilised natural fragment” design pattern. For the fundamentals, see our primer on what peptides are.

    Mechanisms explored in the literature

    The Selank research literature has two main threads:

    • GABAergic / anxiolytic pathways. The most-cited angle is Selank’s reported influence on GABAergic signalling in preclinical anxiety-related models.
    • Immunomodulation. Because it derives from tuftsin, an immune-active peptide, Selank also appears in research on immune-signalling pathways.

    These are mechanisms studied in preclinical research, not approved clinical outcomes. Selank is not an approved therapeutic in most jurisdictions.

    What’s on the market

    Selank is typically sold as lyophilised powder in sealed vials. Research-grade material should be ≥98% HPLC with a batch Certificate of Analysis. It is almost always discussed alongside Semax as the two flagship regulatory peptides in nootropic research.

    Quality considerations when sourcing Selank

    The documentation set is the standard one: mass spectrometry for identity, HPLC purity of ≥98% shown as a chromatogram, and a lot-specific Certificate of Analysis with net peptide content. See our Quality & Analytics page, and current formats in the catalogue.

    Frequently asked questions

    What is Selank?

    Selank is a synthetic heptapeptide based on the immune-active peptide tuftsin, with a stabilising modification. In research it is studied for GABAergic/anxiolytic and immunomodulatory pathways.

    Is Selank an approved drug?

    In most jurisdictions Selank is not an approved medicine; it is handled as a research material for laboratory use only.

    How is Selank related to Semax?

    Both are stabilised Russian regulatory peptides used in nootropic research, but they derive from different natural molecules and are studied for different pathways — Selank for GABAergic/immune signalling, Semax for neurotrophic signalling.

    In summary

    Selank is a tuftsin-derived regulatory peptide studied in preclinical research for GABAergic and immunomodulatory pathways, and paired with Semax. It is not an approved therapeutic, and documentation — ≥98% HPLC purity, mass-spec identity, a lot-specific CoA — is what separates products. See our Quality & Analytics page or browse the catalogue.

    Solis Peptides supplies research peptides for laboratory research use only — not for human or veterinary use, and not a medicine, supplement, or cosmetic. Nothing in this article is medical, dosing, or usage advice.

  • Semax: A Research Profile (ACTH Fragment Analogue)

    Semax is one of the best-known peptides in the nootropic-research category. Originally developed in Russia, it is a synthetic analogue based on a fragment of adrenocorticotropic hormone (ACTH), and it appears frequently in preclinical literature on neurotrophic and neuroprotective pathways. This profile explains what Semax is, the mechanisms studied in research, and what to check when sourcing it.

    This concerns Semax strictly as a research material. The peptides Solis supplies are for laboratory research use only — not for human or veterinary use — and nothing here is medical, dosing, or usage guidance.

    What is Semax?

    Semax is a synthetic peptide derived from the ACTH(4–10) fragment, with an added Pro-Gly-Pro tail that improves its stability. That structural tweak is characteristic of the “regulatory peptide” design approach: take a short active fragment of a natural hormone and stabilise it for research use. For the fundamentals of how such peptides are built, see our primer on what peptides are.

    Mechanisms explored in the literature

    The Semax research literature centres on the nervous system:

    • BDNF and neurotrophic signalling. The most-cited angle is Semax’s reported influence on brain-derived neurotrophic factor (BDNF) and related neurotrophic pathways in research models.
    • Neuroprotection models. Semax has been examined in preclinical models of neural stress and protection.

    These are mechanisms studied in preclinical research, not approved clinical outcomes. Semax is not an approved therapeutic in most jurisdictions and is handled as a research compound.

    What’s on the market

    Semax is typically sold as lyophilised powder in sealed vials, and sometimes as a solution. Research-grade material should be ≥98% HPLC with a batch Certificate of Analysis. It is frequently grouped with Selank as the two flagship Russian regulatory peptides in the nootropic-research space.

    Quality considerations when sourcing Semax

    The documentation that separates credible Semax from an unknown powder is the standard set: mass spectrometry for identity, HPLC purity of ≥98% shown as a chromatogram, and a lot-specific Certificate of Analysis with net peptide content. We document all of this on our Quality & Analytics page, and current formats are in the catalogue.

    Frequently asked questions

    What is Semax?

    Semax is a synthetic peptide based on the ACTH(4–10) fragment with a stabilising Pro-Gly-Pro tail. In research it is studied for neurotrophic and neuroprotective pathways, particularly BDNF.

    Is Semax an approved drug?

    In most jurisdictions Semax is not an approved medicine; it is handled as a research material for laboratory use only and is not intended for human or veterinary use.

    What is Semax studied for?

    In preclinical research it is examined for its reported influence on BDNF and neuroprotective pathways. These are research findings, not approved clinical uses.

    In summary

    Semax is a stabilised ACTH-fragment peptide studied in preclinical research for neurotrophic pathways such as BDNF, and commonly paired with Selank. It is not an approved therapeutic, and documentation — ≥98% HPLC purity, mass-spec identity, a lot-specific CoA — is what separates products. See our Quality & Analytics page or browse the catalogue.

    Solis Peptides supplies research peptides for laboratory research use only — not for human or veterinary use, and not a medicine, supplement, or cosmetic. Nothing in this article is medical, dosing, or usage advice.

  • MOTS-c: A Research Profile of the Mitochondrial-Derived Peptide

    MOTS-c belongs to a fascinating and relatively young category: the mitochondrial-derived peptides (MDPs). Unlike most research peptides, which correspond to fragments of proteins encoded in the cell nucleus, MOTS-c is encoded within the mitochondrial genome — the small, separate ring of DNA inside the cell’s energy organelles. That unusual origin, and its links to metabolic biology, are what make it a distinctive research tool.

    As always, this concerns MOTS-c as a research material only. It is not an approved medicine, and the peptides Solis supplies are for laboratory research use only — not for human or veterinary use. Nothing here is medical, dosing, or usage guidance.

    What is MOTS-c?

    MOTS-c (Mitochondrial ORF of the 12S rRNA type-c) is a short peptide encoded in mitochondrial DNA. This is what sets it apart: the vast majority of peptides are products of nuclear genes, but MDPs like MOTS-c arise from the mitochondrial genome, which is why researchers describe them as “mitochondrial-derived.”

    Its research profile is tied closely to cellular metabolism and energy homeostasis — appropriate for a peptide that comes from the cell’s power plants. For the general fundamentals, see our primer on what peptides are.

    Mechanisms explored in the literature

    The MOTS-c research literature centres on metabolic signalling:

    • The AMPK pathway. MOTS-c is most often studied in relation to AMP-activated protein kinase (AMPK), a central sensor of cellular energy status. This is why MOTS-c is framed as a metabolic-regulation tool compound.
    • Metabolic homeostasis. Research has examined MOTS-c in models of glucose handling, insulin sensitivity, and metabolic stress — as preclinical research, not clinical outcomes.
    • Mitochondrial-nuclear communication. As an MDP, MOTS-c is studied in the broader question of how mitochondria signal to the rest of the cell.

    These are mechanisms studied in research models, and MOTS-c is not an approved therapeutic.

    What’s on the market

    Across research-peptide suppliers, MOTS-c typically appears as:

    • Lyophilised powder in sealed vials, reconstituted in the laboratory.
    • Standalone listings, sometimes grouped with other longevity/metabolic research peptides such as Epitalon.
    • Purity grades. Research-grade material should be ≥98% HPLC, with a batch Certificate of Analysis.

    Quality considerations when sourcing MOTS-c

    For a research buyer, the documentation that separates credible MOTS-c from an unknown powder is the standard set:

    • Mass spectrometry confirming the molecular identity of the peptide for the specific lot.
    • HPLC purity of ≥98%, shown as an actual chromatogram.
    • A lot-specific Certificate of Analysis (CoA), plus clarity on net peptide content.

    We document all of this on our Quality & Analytics page, and current MOTS-c formats are in the catalogue.

    Frequently asked questions

    What is MOTS-c?

    MOTS-c is a mitochondrial-derived peptide — a short peptide encoded within mitochondrial DNA rather than the nuclear genome. In research it is studied mainly in the context of metabolic regulation and the AMPK energy-sensing pathway.

    What makes MOTS-c unusual among peptides?

    Its origin. Most peptides come from nuclear-encoded proteins, but MOTS-c is encoded in the mitochondrial genome, placing it in the distinct class of mitochondrial-derived peptides.

    Is MOTS-c an approved drug?

    No. MOTS-c is not an approved medicine with the major regulators. It is handled as a research material for laboratory use only.

    In summary

    MOTS-c is a mitochondrial-derived peptide whose research profile is built around metabolic regulation and the AMPK energy-sensing pathway, with a distinctive origin in the mitochondrial genome. It is commonly grouped with longevity/metabolic research peptides like Epitalon. It is not an approved therapeutic, and what separates products is documentation: ≥98% HPLC purity, mass-spec identity, and a lot-specific CoA. See our Quality & Analytics page or browse the catalogue.

    Solis Peptides supplies research peptides for laboratory research use only — not for human or veterinary use, and not a medicine, supplement, or cosmetic. Nothing in this article is medical, dosing, or usage advice.

  • Epitalon: A Research Profile of the Pineal Tetrapeptide

    Epitalon (also spelled Epithalon) is one of the most distinctive peptides in the longevity-research category. Where most research peptides are studied around tissue repair or the growth-hormone axis, Epitalon’s literature centres on the pineal gland and, most famously, on telomerase — the enzyme involved in maintaining the protective caps at the ends of chromosomes. This profile explains what Epitalon is, why it draws research interest, and what to check when sourcing it.

    As with everything we publish, this concerns Epitalon as a research material only. It is not an approved medicine, and the peptides Solis supplies are for laboratory research use only — not for human or veterinary use. Nothing here is medical, dosing, or usage guidance.

    What is Epitalon?

    Epitalon is a synthetic tetrapeptide — a chain of just four amino acids (Ala-Glu-Asp-Gly). It was developed as a synthetic version of a peptide fraction originally associated with the pineal gland. Its very short length makes it straightforward to synthesise and characterise, which is part of why it became a widely available research compound.

    Because it derives from pineal-associated material, Epitalon is often described in the literature in the context of the pineal axis and circadian regulation, alongside the telomerase angle it is best known for. For the basics of how short peptides like this are built, see our primer on what peptides are.

    Mechanisms explored in the literature

    Two threads dominate the Epitalon research literature:

    • Telomerase activity. The most-cited research angle is Epitalon’s reported association with telomerase, the enzyme that adds repeats to telomeres. Because telomere length is a marker studied in the biology of cellular ageing, this is why Epitalon is grouped with “longevity” research peptides.
    • Pineal and circadian context. As a pineal-derived sequence, Epitalon appears in research discussing melatonin regulation and circadian rhythm models.

    It is worth stating the framing plainly: these are mechanisms examined in preclinical research, not approved clinical outcomes. Epitalon is not an approved therapeutic.

    What’s on the market

    Across research-peptide suppliers, Epitalon typically appears as:

    • Lyophilised powder in sealed vials, reconstituted in the laboratory, commonly in small milligram sizes.
    • “Epitalon” vs “Epithalon” labelling — the same compound, two spellings; documentation, not spelling, is what matters.
    • Purity grades. Research-grade material should be ≥98% HPLC, with a batch Certificate of Analysis.

    Quality considerations when sourcing Epitalon

    Because Epitalon is short and inexpensive to make, the market carries a wide range of quality. The documentation that separates credible material from an unknown powder is the standard set:

    • Mass spectrometry confirming the identity of the tetrapeptide for the specific lot.
    • HPLC purity of ≥98%, shown as an actual chromatogram.
    • A lot-specific Certificate of Analysis (CoA), plus clarity on net peptide content.

    We document all of this on our Quality & Analytics page, and current Epitalon formats are in the catalogue.

    Frequently asked questions

    What is Epitalon?

    Epitalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) based on a peptide fraction associated with the pineal gland. In research it is studied for its reported links to telomerase activity and circadian/pineal biology.

    Why is Epitalon associated with longevity research?

    Because its most-cited research angle is telomerase — the enzyme that maintains telomeres, whose length is a marker studied in cellular-ageing biology.

    Is Epitalon an approved drug?

    No. Epitalon is not an approved medicine with the major regulators. It is handled as a research material for laboratory use only.

    In summary

    Epitalon is a short synthetic tetrapeptide from the pineal-peptide family, studied chiefly for its reported association with telomerase and circadian biology — the reason it sits in the longevity-research category alongside peptides like MOTS-c. It is not an approved therapeutic, and as with any research peptide, documentation is what separates products: ≥98% HPLC purity, mass-spec identity, and a lot-specific CoA. See our Quality & Analytics page or browse the catalogue.

    Solis Peptides supplies research peptides for laboratory research use only — not for human or veterinary use, and not a medicine, supplement, or cosmetic. Nothing in this article is medical, dosing, or usage advice.

  • How to Read a Peptide Certificate of Analysis (CoA)

    A Certificate of Analysis (CoA) is the single most useful document a research-peptide buyer can ask for — and one of the most misunderstood. A good CoA turns “trust me, it’s pure” into “here is the evidence.” A bad one is a logo on a PDF. This article explains what a research-peptide CoA should contain, how to read each part, and how to tell a genuine batch document from a rubber stamp.

    Everything here concerns peptides as research materials. The peptides Solis supplies are for laboratory research use only — not for human or veterinary use — and nothing below is medical, dosing, or usage guidance.

    What a Certificate of Analysis is

    A CoA is a lab report tied to a specific batch (lot) of material. It records the tests run on that lot and their results, so a buyer can verify what they are actually receiving instead of relying on the label. The key word is specific: a CoA that isn’t tied to a named batch, with a date, tells you nothing about the vial in your hand.

    The three questions a good CoA answers

    For a research peptide, a credible CoA answers three distinct questions — and it takes three different measurements to do it. (We cover the first in depth in our piece on what ≥98% HPLC purity really means.)

    • Is it pure? — the HPLC result, expressed as a percentage (e.g. ≥98%), ideally shown with the actual chromatogram rather than just a number. This tells you how much of the detected material is the target compound versus synthesis by-products.
    • Is it the right molecule? — the mass spectrometry (MS) result, which confirms molecular weight and therefore identity. Purity and identity are separate: a sample can be 99% one thing that is the wrong thing.
    • How much peptide is actually there? — net peptide content, which accounts for water, counter-ions (salts), and residual solvents in the vial. A “5 mg” vial is 5 mg of material, not necessarily 5 mg of peptide.

    A CoA that shows all three is doing its job. One that shows only a purity percentage is a partial picture.

    Reading each section

    • Product and batch identifiers. Product name, sequence (or molecular formula), lot number, and date. No lot number, no accountability.
    • Appearance. Usually “white to off-white lyophilised powder.” Minor, but a real report includes it.
    • HPLC purity and chromatogram. Look for one sharp, dominant peak with a clean baseline. A cluster of near-peaks suggests related impurities. The number should match the trace.
    • Mass spectrometry. The measured mass should match the theoretical mass for the sequence. This is the identity check.
    • Net peptide content. Often reported separately; it is what tells you the true peptide mass.
    • Who tested it. In-house versus independent third-party testing. Third-party results are harder to fake and carry more weight.

    Spotting a rubber stamp

    A weak or fake CoA tends to share tells: no batch number or date; a purity number with no chromatogram; no mass-spec data at all; a generic document reused across products; or results that are suspiciously identical batch after batch. Real analytics vary slightly from lot to lot — perfection repeated is a red flag, not a green one.

    Frequently asked questions

    What should a research-peptide CoA include?

    At minimum: product and batch identifiers, HPLC purity with the chromatogram, mass-spectrometry identity confirmation, and net peptide content — ideally with the name of the lab that performed the testing.

    Is a purity percentage alone enough?

    No. Purity answers “how much of the detected material is the target,” but not “is it the correct molecule” (mass spec) or “how much peptide is really in the vial” (net peptide content).

    Why does third-party testing matter?

    Because an independent lab has no incentive to flatter the result. A third-party CoA is far harder to fabricate than an in-house claim.

    In summary

    A Certificate of Analysis is how a research buyer replaces trust with evidence. A real one is batch-specific and answers three separate questions — purity, identity, and net peptide content — ideally verified by an independent third-party lab. Anything less is a claim, not proof. See how Solis documents this on the Quality & Analytics page, or browse the catalogue.

    Solis Peptides supplies research peptides for laboratory research use only — not for human or veterinary use, and not a medicine, supplement, or cosmetic. Nothing in this article is medical, dosing, or usage advice.